These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25932262)

  • 1. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.
    Zhang Y; Feng Y; Cao B; Tian Q
    Int J Clin Exp Med; 2015; 8(2):2954-7. PubMed ID: 25932262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
    Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
    J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Hepatic Encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes.
    Abid S; Kamran M; Abid A; Butt N; Awan S; Abbas Z
    Sci Rep; 2020 Jun; 10(1):10079. PubMed ID: 32572109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
    Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
    Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy.
    Lunia MK; Sharma BC; Sachdeva S
    Hepatol Int; 2013 Mar; 7(1):268-73. PubMed ID: 26201641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.
    Sharma K; Pant S; Misra S; Dwivedi M; Misra A; Narang S; Tewari R; Bhadoria AS
    Saudi J Gastroenterol; 2014; 20(4):225-32. PubMed ID: 25038208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.
    Wang MW; Ma WJ; Wang Y; Ma XH; Xue YF; Guan J; Chen X
    Front Microbiol; 2023; 14():1091167. PubMed ID: 37032856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.
    Barkin JA; Keihanian T; Barkin JS; Antequera CM; Moshiree B
    Rev Gastroenterol Peru; 2019; 39(2):111-115. PubMed ID: 31333225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study.
    Rathi S; Chopra M; Chouduri G; Sharma P; Madan K; Chhabra M; Rai RR; Govil A; Konar A; Goenka M; Agarwal M; Mukherjee J; Thorat V; Salunkhe S; Abraham P; Nagral A; Jhaveri A; Bhat N; Varghese J; R S A; Ravishankar ; Reddy DC; Dhiman RK
    J Clin Exp Hepatol; 2019; 9(4):476-483. PubMed ID: 31516264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
    Sakamaki A; Yokoyama K; Yamazaki F; Kamimura H; Kamimura K; Takamura M; Yokoyama J; Terai S
    Intern Med; 2020 Aug; 59(15):1849-1853. PubMed ID: 32321898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.
    Ghosh G; Jesudian AB
    J Clin Exp Hepatol; 2019; 9(2):257-267. PubMed ID: 31024208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Age-and, education-corrected number connection test and digit symbol test in diagnosis of minimal hepatic encephalopathy].
    Hao L; Hu Y; Hou X
    Zhonghua Gan Zang Bing Za Zhi; 2015 Jul; 23(7):533-7. PubMed ID: 26398846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis.
    Zhang Y; Feng Y; Cao B; Tian Q
    Arch Med Sci; 2016 Jun; 12(3):592-6. PubMed ID: 27279853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
    Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
    Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.
    Yokoyama K; Sakamaki A; Takahashi K; Naruse T; Sato C; Kawata Y; Tominaga K; Abe H; Sato H; Tsuchiya A; Kamimura K; Takamura M; Yokoyama J; Terai S
    PLoS One; 2022; 17(2):e0264459. PubMed ID: 35213654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity.
    Casanova-Ferrer F; Gallego JJ; Fiorillo A; Urios A; Ríos MP; León JL; Ballester MP; Escudero-García D; Kosenko E; Belloch V; Montoliu C
    J Transl Med; 2024 Jan; 22(1):49. PubMed ID: 38217008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal.
    Pawar VB; Surude RG; Sonthalia N; Zanwar V; Jain S; Contractor Q; Rathi PM
    J Clin Transl Hepatol; 2019 Dec; 7(4):304-312. PubMed ID: 31915599
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver.
    Bale A; Pai CG; Shetty S; Balaraju G; Shetty A
    J Clin Exp Hepatol; 2018 Jun; 8(2):156-161. PubMed ID: 29892178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.